Introduction: Various approaches are required to prevent and treat heterogeneity-based prostate cancer, and metformin, which has a good toxic profile and is very inexpensive, is known to have anticancer effects, so we want to analyze its effect. Methods: From January 2010 to December 2019, the analysis was conducted using a retrospective cohort using the National Health Insurance Service database. The Metformin non-administration group was defined as a subject who had never been prescribed Metformin during the study period or did not meet the Metformin customization (Metformin usage period <180 days). The prevalence of prostate cancer according to metformin administration and the risk according to the cumulative amount of metformin administration were analyzed. Results: A total of 105,216 people were included in this study, of which 59,844 metformin group and 45,372 metformin non-administration group were analyzed. When calculating HR according to the cumulative period of administration of Metformin, it was found that the longer the cumulative period of administration of Metformin, the lower the HR for the risk of developing prostate cancer. (Q2 HR=0.791 95% CI: 0.773-0.81, Q3 HR=0.634 95% CI: 0.62-0.649, Q4 HR=0.571 95% CI: 0.558-0.585) HR tended to decrease with the cumulative duration of Metformin administration. Conclusions: Through this study, it was confirmed that the risk of prostate cancer was lowered according to the dosage of metformin. Metformin should be considered in new strategies in the treatment and prevention of prostate cancer characterized by heterogeneity. SOURCE OF Funding: None
